PubMed
Thymosin alpha 1: A comprehensive review of the literature
Romani et al., 2020
Immune SupportCompoundable (US) — Approved InternationallyA
Thymosin Alpha-1
Tα1 / Zadaxin
Thymosin alpha-1 (Tα1, brand: Zadaxin) is a 28-amino acid peptide naturally produced by the thymus gland that plays a central role in modulating T-cell maturation and immune response. Approved in 40+ countries for hepatitis B, hepatitis C treatment adjuvancy, and as immune support in cancer patients. In the US, available through compounding pharmacies for immune support. Studied for COVID-19 severity reduction.
Observational report only — live community data. Not medical advice. Does not recommend doses, protocols, or treatments.
- Studies cited
- 8
- Research grade
- A
- Experience
- 100
- Activity
- 58
Overall check-ins
Trackers & reports
Overview
About Thymosin Alpha-1
Thymosin alpha-1 (Tα1, brand: Zadaxin) is a 28-amino acid peptide naturally produced by the thymus gland that plays a central role in modulating T-cell maturation and immune response. Approved in 40+ countries for hepatitis B, hepatitis C treatment adjuvancy, and as immune support in cancer patients. In the US, available through compounding pharmacies for immune support. Studied for COVID-19 severity reduction.
- Category
- Immune Support
- Regulatory status
- Compoundable (US) — Approved Internationally
- Also known as
- Tα1 / Zadaxin
- Self-reports
- 6
Community
What 6 users report
6 community reports
Overall experience
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 100% · Mixed 0% · Unfavorable overall 0%
Most reported benefits
Benefits users selected when logging a favorable or mixed check-in.
Recovery
6
Self-reported dose per injection
Median bucket: 0.4–0.6 mg · Most common: 0.4–0.6 mg
Reports span 0.4–2 mg
0.4–0.6 mg
4
1–2 mg
2
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Research
Cited research (6)
Source
PubMed
Thymosin alpha 1 in infectious diseases: Perspectives for tomorrow
Tuthill et al., 2017
PubMed
Thymosin alpha 1 as adjuvant therapy for melanoma and other cancers
Garaci et al., 2014
ClinicalTrials.gov
Thymosin alpha-1 studies on ClinicalTrials.gov
ClinicalTrials.gov, 2024
PubMed
Immunotherapy for hepatitis B in the direct acting antiviral era: Reevaluating the thymosin α1 efficacy trials in the light of a combination therapy approach
Naylor et al., 2018
PubMed
Safety and Efficacy of Nucleic Acid Polymers in Monotherapy and Combined with Immunotherapy in Treatment-Naive Bangladeshi Patients with HBeAg+ Chronic Hepatitis B Infection
Al-Mahtab et al., 2016
Tools
Explore more
Explore
More ways to learn about Thymosin Alpha-1 from observational PeptIQ data.
Compare with
Help
Frequently asked
What do PeptIQ users report about Thymosin Alpha-1?
This page summarizes 6 anonymized self-reports from PeptIQ users who track Thymosin Alpha-1, including commonly reported effects and co-tracked peptides. These are observational patterns, not clinical outcomes.
How do side effects relate to overall experience for Thymosin Alpha-1?
PeptIQ separates overall check-in ratings (favorable, mixed, or unfavorable) from logged side effects like nausea or fatigue. Users often report benefits and side effects in the same check-in — a high experience score does not mean zero side effects were noted.
What research is cited for Thymosin Alpha-1?
6 sources are linked on this page, including PubMed articles, clinical trial registries, and FDA labels where applicable. Citations describe published research — not recommendations.
Is Thymosin Alpha-1 safe to use?
This wiki does not assess safety or recommend use. Thymosin Alpha-1 is listed as Compoundable (US) — Approved Internationally. Consult a licensed clinician for personal medical decisions.
What are the purported benefits and uses of Thymosin Alpha-1?
Research, primarily in animal models, suggests Thymosin Alpha-1 may have a wide range of therapeutic potentials due to its ability to promote angiogenesis (formation of new blood vessels), stimulate collagen synthesis, and modulate inflammatory responses.
SourceWhat is the legal status of Thymosin Alpha-1?
Thymosin Alpha-1 is not approved by the FDA for any human use. There is no legal basis for selling it as a drug, food, or dietary supplement in the United States. The FDA has classified Thymosin Alpha-1 as a Category 2 bulk drug substance, which explicitly prohibits licensed compounding pharmacies from using it in compounded medications.
SourceWhat are the known or theoretical side effects and risks of Thymosin Alpha-1?
The safety and effectiveness of Thymosin Alpha-1 have not been thoroughly evaluated in humans through rigorous clinical trials. This lack of human data means that safe dosages, short-term side effects, and long-term health consequences are largely unknown.
SourceWhat is the current state of research on Thymosin Alpha-1?
While there are over 200 published studies on Thymosin Alpha-1, the vast majority are animal or in vitro (cell) studies. These preclinical studies consistently show positive results across various tissue types. However, there is a significant lack of comprehensive human clinical trial data.
Source